KOBE, Japan, May 17 /PRNewswire/ -- Carna Biosciences, Inc. and Enamine Ltd. jointly announced the signing of a collaboration agreement to cooperate on discovery and development of lead compounds against targeted kinase.
Carna Biosciences has succeeded in development of assay systems of more than 160 kinases utilizing its proprietary technologies and know-how on gene cloning, active protein expression, purification and screening. Enamine is one of the top providers of screening libraries for pre-clinical drug discovery and owns over 8,000 compounds as kinase-focused libraries.
Carna Biosciences and Enamine have selected a kinase as target, which is reported to have relationship to Cancer. Enamine is responsible for developing kinase-focused libraries against targeted kinase utilizing docking methodologies and Carna Biosciences is responsible for screening the libraries against the targeted kinase. The companies intend to license the lead compounds developed by the collaboration to pharmaceutical companies.
“By collaborating with Enamine, Carna Biosciences will be able to find novel lead compounds attractive for pharmaceutical companies,” said Kohichiro Yoshino, President and CEO of Carna Biosciences. “The unsurpassed quality and reliability of our assay and screening technologies will help us, together with Enamine’s know-how on development of compound libraries, to continue the expansion of our kinase-focused drug discovery businesses.”
“Our expertise in the computer assisted structure-based techniques combined with original custom tailored chemistry will result in novel lead compounds,” said Dr. Andrei Tolmachev, President and CEO of Enamine. “The technologies of Carna Biosciences and Enamine are so complementary that I am confident in the outcome of this collaborative research.”
About Carna Biosciences Inc.
Carna Biosciences, Inc. (http://www.carnabio.com), founded in April 2003, is a Japanese biotechnology company conducting intercellular signaling-based drug discovery programs, as well as providing drug discovery services to pharmaceutical companies, with proprietary technologies in gene cloning, active kinase protein expression, protein purification and homogeneous assay development. The company provides products and services including protein kinases, profiling and screening services, assay development services and crystallography products and services.
About Enamine Ltd.
Enamine Ltd. (http://www.enamine.net), a Ukrainian company is one of the top providers of custom chemistry services and screening libraries for pre- clinical drug discovery and agro chemistry worldwide. Currently Enamine offers its customers one of the largest and the most chemically diverse proprietary screening collection of small organic compounds in the world. Enamine has earned a reputation as a leading provider of a number of chemistry services, including custom synthesis and lead-oriented services. Keeping close ties with Ukrainian academic research centers, Enamine explores a variety of prospective topics in contemporary organic chemistry, such as assymmetric synthesis, synthesis of fluorescent dyes and peptidomimetics, and supports other projects aimed at the development of fundamental research in organic chemistry.
Carna Biosciences, Inc.
CONTACT: Kyoko Omoda, Manager of Corporate Planning, Carna Biosciences,Inc., +81-78-302-7039, Fax: +81-78-302-7086, marcom@carnabio.com; or DmytroKovalskyy, Group Leader of Molecular Modelling Group, Enamine Ltd.,+38-44-537-3218, Fax: +38-44-537-3253, D.Kovalskyy@enamine.net
